56 related articles for article (PubMed ID: 10365768)
1. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
Astermark J; Donfield SM; Gomperts ED; Schwarz J; Menius ED; Pavlova A; Oldenburg J; Kessing B; DiMichele DM; Shapiro AD; Winkler CA; Berntorp E;
Blood; 2013 Feb; 121(8):1446-54. PubMed ID: 23223434
[TBL] [Abstract][Full Text] [Related]
2. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
Baglin T; Beacham E
Thromb Haemost; 1998 Dec; 80(6):1036-7. PubMed ID: 9869186
[No Abstract] [Full Text] [Related]
3. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
Rieger A; Roisenberg I
Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489
[No Abstract] [Full Text] [Related]
4. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution.
van den Brink EN; Timmermans SM; Turenhout EA; Bank CM; Fijnvandraat K; Voorberg J; Peters M
Thromb Haemost; 1999 May; 81(5):723-6. PubMed ID: 10365744
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor development in a multitransfused patient with severe haemophilia A.
van den Berg HM; Roosendaal G; Voorberg J; Mauser-Bunschoten EP
Thromb Haemost; 1999 Jul; 82(1):151-2. PubMed ID: 10456472
[No Abstract] [Full Text] [Related]
6. Reactivation of chronic hepatitis C virus infection by immunoadsorption in factor VIII inhibitor haemophilia.
Rommel F; Toepfer M; Eberle J; Schiffl H; Spannagl M; Schramm W
Thromb Haemost; 2000 Oct; 84(4):733-4. PubMed ID: 11057884
[No Abstract] [Full Text] [Related]
7. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
Yee TT; Lee CA
Thromb Haemost; 1999 May; 81(5):852. PubMed ID: 10365768
[No Abstract] [Full Text] [Related]
8. Inhibitors in young boys with haemophilia.
Lusher JM
Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
[TBL] [Abstract][Full Text] [Related]
9. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
White GC; Greenwood R; Escobar M; Frelinger JA
Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
[TBL] [Abstract][Full Text] [Related]
10. Antibodies to factor VIII in hemophilia A patients.
Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
Vox Sang; 2000; 78 Suppl 2():187-90. PubMed ID: 10938950
[TBL] [Abstract][Full Text] [Related]
11. Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors.
Dasgupta S; Navarrete AM; Delignat S; Wootla B; Andre S; Nagaraja V; Lacroix-Desmazes S; Kaveri SV
Immunol Lett; 2007 May; 110(1):23-8. PubMed ID: 17467813
[TBL] [Abstract][Full Text] [Related]
12. Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response.
Penner JA
Haemophilia; 2001 Jan; 7(1):103-8. PubMed ID: 11136390
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
